HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
afatinib Resistant: A2 - Guideline
|
afatinib Resistant: A2 - Guideline
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
trastuzumab Resistant: A2 - Guideline
|
trastuzumab Resistant: A2 - Guideline
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
ado-trastuzumab emtansine Sensitive: A2 - Guideline
|
ado-trastuzumab emtansine Sensitive: A2 - Guideline
|
HER-2 mutation
|
Solid Tumor
|
HER-2 mutation
|
Solid Tumor
|
BDTX-189 Sensitive: B - Late Trials
|
BDTX-189 Sensitive: B - Late Trials
|
HER-2 mutation
|
Breast Cancer
|
HER-2 mutation
|
Breast Cancer
|
ribociclib Sensitive: B - Late Trials
|
ribociclib Sensitive: B - Late Trials
|
HER-2 mutation
|
Solid Tumor
|
HER-2 mutation
|
Solid Tumor
|
tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
|
tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Hormone Receptor Positive Breast Cancer
|
HER-2 mutation
|
Hormone Receptor Positive Breast Cancer
|
trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
|
trastuzumab + neratinib Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Gastric Cancer
|
HER-2 mutation
|
Gastric Cancer
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Lung Cancer
|
HER-2 mutation
|
Lung Cancer
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Urothelial Cancer
|
HER-2 mutation
|
Urothelial Cancer
|
afatinib Sensitive: C2 – Inclusion Criteria
|
afatinib Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
|
tarloxotinib bromide Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Solid Tumor
|
HER-2 mutation
|
Solid Tumor
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Cervical Cancer
|
HER-2 mutation
|
Cervical Cancer
|
neratinib Sensitive: C2 – Inclusion Criteria
|
neratinib Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
pyrotinib Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Breast Cancer
|
HER-2 mutation
|
Breast Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
fam-trastuzumab deruxtecan-nxki Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Gastroesophageal Junction Adenocarcinoma
|
HER-2 mutation
|
Gastroesophageal Junction Adenocarcinoma
|
pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab + margetuximab Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
Breast Cancer
|
HER-2 mutation
|
Breast Cancer
|
neratinib Sensitive: C2 – Inclusion Criteria
|
neratinib Sensitive: C2 – Inclusion Criteria
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
trastuzumab + neratinib Sensitive: C3 – Early Trials
|
trastuzumab + neratinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
neratinib + temsirolimus Sensitive: C3 – Early Trials
|
neratinib + temsirolimus Sensitive: C3 – Early Trials
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
U3-1402 Sensitive: C3 – Early Trials
|
U3-1402 Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Biliary Tract Cancer
|
HER-2 mutation
|
Biliary Tract Cancer
|
neratinib Sensitive: C3 – Early Trials
|
neratinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
LUAD
|
HER-2 mutation
|
LUAD
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 mutation
|
SCCHN
|
HER-2 mutation
|
SCCHN
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
cetuximab + ISU104 Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Thymic Carcinoma
|
HER-2 mutation
|
Thymic Carcinoma
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Solid Tumor
|
HER-2 mutation
|
Solid Tumor
|
KN046 + KN026 Sensitive: C3 – Early Trials
|
KN046 + KN026 Sensitive: C3 – Early Trials
|
HER-2 mutation
|
CRC
|
HER-2 mutation
|
CRC
|
pyrotinib Sensitive: C3 – Early Trials
|
pyrotinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
PD-L1 inhibitor Resistant: C3 – Early Trials
|
HER-2 mutation
|
LUAD
|
HER-2 mutation
|
LUAD
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
HER2 Positive Breast Cancer
|
HER-2 mutation
|
HER2 Positive Breast Cancer
|
trastuzumab Resistant: C3 – Early Trials
|
trastuzumab Resistant: C3 – Early Trials
|
HER-2 mutation
|
CRC
|
HER-2 mutation
|
CRC
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
fam-trastuzumab deruxtecan-nxki Sensitive: C3 – Early Trials
|
HER-2 mutation
|
LUAD
|
HER-2 mutation
|
LUAD
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
ado-trastuzumab emtansine Sensitive: C3 – Early Trials
|
HER-2 mutation
|
HER2 Positive Breast Cancer
|
HER-2 mutation
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: C3 – Early Trials
|
neratinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
durvalumab Resistant: C3 – Early Trials
|
durvalumab Resistant: C3 – Early Trials
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Gastric Cancer
|
HER-2 mutation
|
Gastric Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Gastric Cancer
|
HER-2 mutation
|
Gastric Cancer
|
disitamab vedotin Sensitive: C3 – Early Trials
|
disitamab vedotin Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Uterine Cancer
|
HER-2 mutation
|
Uterine Cancer
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
trastuzumab + pertuzumab Sensitive: C3 – Early Trials
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Ovarian Cancer
|
HER-2 mutation
|
Ovarian Cancer
|
bevacizumab Resistant: C3 – Early Trials
|
bevacizumab Resistant: C3 – Early Trials
|
HER-2 mutation
|
LUAD
|
HER-2 mutation
|
LUAD
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Triple Negative Breast Cancer
|
HER-2 mutation
|
Triple Negative Breast Cancer
|
trastuzumab + neratinib Sensitive: C3 – Early Trials
|
trastuzumab + neratinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
trastuzumab + neratinib Sensitive: C3 – Early Trials
|
trastuzumab + neratinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
neratinib Sensitive: C3 – Early Trials
|
neratinib Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Solid Tumor
|
HER-2 mutation
|
Solid Tumor
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Cholangiocarcinoma
|
HER-2 mutation
|
Cholangiocarcinoma
|
trastuzumab Resistant: C4 – Case Studies
|
trastuzumab Resistant: C4 – Case Studies
|
HER-2 mutation
|
Cholangiocarcinoma
|
HER-2 mutation
|
Cholangiocarcinoma
|
lapatinib Resistant: C4 – Case Studies
|
lapatinib Resistant: C4 – Case Studies
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
HER-2 mutation
|
Estrogen Receptor Positive Breast Cancer
|
tucatinib Sensitive: C4 – Case Studies
|
tucatinib Sensitive: C4 – Case Studies
|
HER-2 mutation
|
Ovarian Cancer
|
HER-2 mutation
|
Ovarian Cancer
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Ovarian Cancer
|
HER-2 mutation
|
Ovarian Cancer
|
neratinib Sensitive: D – Preclinical
|
neratinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Gastroesophageal Cancer
|
HER-2 mutation
|
Gastroesophageal Cancer
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Gastroesophageal Cancer
|
HER-2 mutation
|
Gastroesophageal Cancer
|
neratinib Sensitive: D – Preclinical
|
neratinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Gastroesophageal Cancer
|
HER-2 mutation
|
Gastroesophageal Cancer
|
dasatinib + neratinib Sensitive: D – Preclinical
|
dasatinib + neratinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Ovarian Cancer
|
HER-2 mutation
|
Ovarian Cancer
|
dasatinib + neratinib Sensitive: D – Preclinical
|
dasatinib + neratinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Cervical Cancer
|
HER-2 mutation
|
Cervical Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Solid Tumor
|
HER-2 mutation
|
Solid Tumor
|
eFT226 Sensitive: D – Preclinical
|
eFT226 Sensitive: D – Preclinical
|
HER-2 mutation
|
NSCLC
|
HER-2 mutation
|
NSCLC
|
JBJ-08–178–01 Sensitive: D – Preclinical
|
JBJ-08–178–01 Sensitive: D – Preclinical
|